Clinical Research Directory
Browse clinical research sites, groups, and studies.
First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
Sponsor: Qilu Hospital of Shandong University
Summary
This prospective observational study aims to evaluate the efficacy and safety of immune checkpoint inhibitors as first-line and neoadjuvant therapy for advanced gastric cancer, while also investigating relevant biomarkers to better understand their role in immunotherapy outcomes
Official title: Prospective Cohort Study on the Efficacy, Adverse Effects, and Biomarkers of First-Line/Neoadjuvant Therapy With Immune Checkpoint Inhibitors Combined With Chemotherapy in Advanced Gastric Cancer
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2022-01-15
Completion Date
2028-01-15
Last Updated
2024-12-11
Healthy Volunteers
No
Interventions
ICI plus Chemothearpy
This intervention involves the administration of immune checkpoint inhibitors (ICIs) in combination with standard chemotherapy.
Chemotherapy
This intervention involves the administration of standard chemotherapy alone.
Locations (1)
Qilu Hospital of Shandong University
Jinan, Shandong, China